Fresenius SE KGaA (FRE) Stock Overview
A health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
FRE Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€61.46
FV
41.5% undervalued intrinsic discount7.00%
Revenue growth p.a.
892
users have viewed this narrative8users have liked this narrative
2users have commented on this narrative
16users have followed this narrative
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €35.94 |
| 52 Week High | €52.96 |
| 52 Week Low | €35.11 |
| Beta | 0.86 |
| 1 Month Change | -11.93% |
| 3 Month Change | -22.54% |
| 1 Year Change | -18.06% |
| 3 Year Change | 38.87% |
| 5 Year Change | -20.55% |
| Change since IPO | 3,083.37% |
Recent News & Updates
Narrative Update • Jun 02
FRE: Digital Healthcare Push And Dividend Stream Will Support Future Upside
The analyst price target for Fresenius SE KGaA has been adjusted slightly lower to about €54.79 from roughly €55.22, with analysts citing updated fair value estimates and modest changes to discount rate and growth assumptions following recent target revisions at Citi, Morgan Stanley and JPMorgan. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in Fresenius SE KGaA, with one major bank setting a target at €56.60, which sits above the current average of about €54.79.Narrative Update • May 09
FRE: Dividend Visibility And Higher Margins Will Support Future Upside
Fresenius SE KGaA's updated analyst price target has edged down by about €0.25, as analysts balance slightly higher revenue growth and profit margin assumptions against a higher discount rate and a more conservative future P/E, in line with mixed recent target revisions from major banks. Analyst Commentary Recent Street research on Fresenius SE KGaA reflects a mix of optimism on earnings potential and caution around valuation and execution risk.Narrative Update • Apr 23
FRE: Dividend Policy And Higher Payout Range Will Support Future Upside
Analysts have trimmed the fair value estimate for Fresenius SE KGaA by about €0.43 to €55.47. This reflects a mix of recent price target increases from JPMorgan, Deutsche Bank and Citi, as well as selective cuts from Morgan Stanley as they adjust assumptions around growth, margins and future P/E.Recent updates
Narrative Update • Jun 02
FRE: Digital Healthcare Push And Dividend Stream Will Support Future Upside
The analyst price target for Fresenius SE KGaA has been adjusted slightly lower to about €54.79 from roughly €55.22, with analysts citing updated fair value estimates and modest changes to discount rate and growth assumptions following recent target revisions at Citi, Morgan Stanley and JPMorgan. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in Fresenius SE KGaA, with one major bank setting a target at €56.60, which sits above the current average of about €54.79.Narrative Update • May 09
FRE: Dividend Visibility And Higher Margins Will Support Future Upside
Fresenius SE KGaA's updated analyst price target has edged down by about €0.25, as analysts balance slightly higher revenue growth and profit margin assumptions against a higher discount rate and a more conservative future P/E, in line with mixed recent target revisions from major banks. Analyst Commentary Recent Street research on Fresenius SE KGaA reflects a mix of optimism on earnings potential and caution around valuation and execution risk.Narrative Update • Apr 23
FRE: Dividend Policy And Higher Payout Range Will Support Future Upside
Analysts have trimmed the fair value estimate for Fresenius SE KGaA by about €0.43 to €55.47. This reflects a mix of recent price target increases from JPMorgan, Deutsche Bank and Citi, as well as selective cuts from Morgan Stanley as they adjust assumptions around growth, margins and future P/E.Narrative Update • Apr 09
FRE: Dividend Framework And Rising Street Confidence Will Shape Future Upside
Analyst price targets for Fresenius SE KGaA have moved higher, with recent estimates ranging from about €56 to €58. Analysts attribute these changes to revised assumptions for growth and profitability, while keeping key valuation inputs such as fair value, discount rate, and forward P/E largely consistent with previous assessments.Narrative Update • Mar 25
FRE: Future Outlook Will Be Driven By Dividend Policy And Strengthening Street Conviction
Analysts have nudged the fair value estimate for Fresenius SE KGaA slightly higher to €55.90, reflecting recent upward revisions to Street price targets in the €56 to €58 range and modest tweaks to long term growth and profitability assumptions. Analyst Commentary Recent Street research on Fresenius SE KGaA has clustered around higher price targets in the mid to high €50s, which broadly lines up with the updated fair value estimate of €55.90.Narrative Update • Mar 08
FRE: Future Outlook Will Be Guided By Dividend Commitment And Mixed Sentiment
Analysts have nudged their price targets on Fresenius SE KGaA higher, with our fair value estimate edging up from €55.69 to €55.83 as they factor in slightly stronger revenue growth assumptions and recent upward target revisions from several banks. Analyst Commentary Recent Street research on Fresenius SE KGaA clusters around incremental target price adjustments, with several banks refining their views rather than radically rethinking the equity story.Narrative Update • Feb 22
FRE: Future Outlook Will Be Guided By Steady Assumptions And Mixed Sentiment
Analysts have updated their view on Fresenius SE KGaA with a revised price target, reflecting the mixed impact of a €5 increase from one research house and a €1 reduction from another, while keeping core assumptions such as fair value, discount rate, revenue growth, profit margin and future P/E essentially unchanged. Analyst Commentary Recent research updates on Fresenius SE KGaA point to a mixed but broadly steady view on the company, with price targets adjusted within a relatively tight range and key modelling inputs such as fair value, discount rate, revenue growth, profit margin and future P/E left largely unchanged.Analysis Article • Feb 16
Fresenius SE KGaA (ETR:FRE) Will Be Looking To Turn Around Its Returns
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...Narrative Update • Feb 07
FRE: Future Outlook Will Be Shaped By Emerging Margin Recovery Confidence
Analysts have inched their fair value estimate for Fresenius SE KGaA higher to €55.69 from €55.47, citing recent price target adjustments across the Street and slightly updated assumptions for the discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts have raised their targets into the mid €50s, which supports the updated fair value estimate around €55.69 and points to some confidence in the current valuation framework.Narrative Update • Jan 24
FRE: Future Outlook Will Be Driven By Rising Margin Recovery Confidence
Fresenius SE KGaA's analyst price targets have edged higher, with our fair value estimate moving from €55.05 to €55.47, as analysts factor in slightly adjusted assumptions on growth, margins and future P/E multiples following a series of recent target increases from major banks. Analyst Commentary Bullish Takeaways Bullish analysts are lifting their price targets into the low to mid €50s, which supports the view that current valuation leaves some headroom if execution on growth and margins lines up with expectations.Narrative Update • Jan 10
FRE: Future Outlook Will Be Driven By Rising Margin Recovery Confidence
Narrative Update The analyst price target for Fresenius SE KGaA has been raised to €55.05 from €54.33, reflecting analysts' updated assumptions around slightly higher profit margins and a modestly higher future P/E multiple, consistent with recent upward target revisions from the Street. Analyst Commentary Recent Street research around Fresenius SE KGaA has centered on a series of upward revisions to published price targets, alongside supportive ratings such as Buy and Overweight.Narrative Update • Dec 25
FRE: Future Earnings Outlook Will Be Driven By Improving Margin Recovery Confidence
The analyst price target for Fresenius SE KGaA has inched higher to about EUR 54.33 from roughly EUR 54.26, as analysts factor in a slightly richer future earnings multiple and continued revenue growth despite modestly lower margin assumptions. Analyst Commentary Bullish analysts have recently raised their price targets for Fresenius SE KGaA into the mid 50 euro range, reflecting greater confidence in the company’s ability to execute on its growth plans and sustain improving fundamentals.Analysis Article • Dec 15
Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult
With a price-to-earnings (or "P/E") ratio of 24.5x Fresenius SE & Co. KGaA ( ETR:FRE ) may be sending bearish signals...Narrative Update • Dec 10
FRE: Future Earnings Outlook Will Be Driven By Rising Profitability Expectations
The analyst price target for Fresenius SE KGaA has been nudged higher to approximately EUR 54.26 from about EUR 53.83, as analysts cite gradually improving revenue growth and profit margin expectations, along with ongoing upward revisions to external price targets. Analyst Commentary Bullish analysts highlight that the series of upward target revisions reflects growing confidence in Fresenius SE KGaA's ability to execute on its strategic plan.Analysis Article • Nov 28
When Should You Buy Fresenius SE & Co. KGaA (ETR:FRE)?
Today we're going to take a look at the well-established Fresenius SE & Co. KGaA ( ETR:FRE ). The company's stock saw...Narrative Update • Nov 26
FRE: Future Earnings Outlook Will Be Driven By Upward Price Revisions
Fresenius SE KGaA's analyst fair value estimate has edged up slightly from €53.40 to €53.83, as analysts point to supportive updates from major banks raising their price targets on the stock. Analyst Commentary Recent updates from major investment banks have led to heightened attention on Fresenius SE KGaA, with several analysts revising their outlooks and valuations upward.Narrative Update • Nov 11
FRE: Future Earnings Outlook Will Reflect Balanced Profit And Risk Expectations
The analyst fair value price target for Fresenius SE KGaA has been raised from €52.36 to €53.40. This change reflects broadly improved expectations from analysts based on strengthening revenue growth and profit margin forecasts.Narrative Update • Oct 28
Elderly Demand And Biosimilars Will Drive Next Phase Of Healthcare
The analyst consensus price target for Fresenius SE KGaA has been increased from €50.33 to €52.36. This change reflects analysts' expectations of modest revenue growth and improved fair value assessments.Narrative Update • Oct 14
Global Elderly Demand And Biosimilars Will Transform Healthcare
Narrative Update on Fresenius SE KGaA Analysts have raised their price target for Fresenius SE KGaA, increasing it from €49.61 to €50.33. They cite improved revenue growth and profit margin outlooks as the basis for the adjustment.Analysis Article • Sep 22
Fresenius SE KGaA (ETR:FRE) Will Be Hoping To Turn Its Returns On Capital Around
Ignoring the stock price of a company, what are the underlying trends that tell us a business is past the growth phase...Narrative Update • Sep 03
Global Elderly Demand And Biosimilars Will Transform Healthcare
Both the Future P/E and Net Profit Margin for Fresenius SE KGaA remained essentially stable, underpinning the marginal increase in the consensus analyst price target from €49.04 to €49.61. What's in the News Fresenius is leading the EASYGEN consortium, a public-private EU-funded initiative aiming to accelerate and cost-optimize CAR-T cell therapy manufacturing, making it more accessible across Europe using modular, hospital-based platforms.Analysis Article • Jul 06
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 21
Investors Holding Back On Fresenius SE & Co. KGaA (ETR:FRE)
There wouldn't be many who think Fresenius SE & Co. KGaA's ( ETR:FRE ) price-to-earnings (or "P/E") ratio of 19.8x is...
New Narrative • Nov 07
Biopharma Innovations And Critical Growth Initiatives Propel Earnings And Margin Expansion
Strategic initiatives focused on productivity and organic growth are expected to enhance operational efficiency and drive margin expansion.Shareholder Returns
| FRE | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -2.7% | -3.5% | -0.3% |
| 1Y | -18.1% | -18.9% | 1.9% |
Return vs Industry: FRE matched the German Healthcare industry which returned -18.9% over the past year.
Return vs Market: FRE underperformed the German Market which returned 1.9% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 6.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FRE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 177,783 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | €20.53b |
| Earnings (TTM) | €1.51b |
| Revenue (TTM) | €22.99b |
13.4x
P/E Ratio0.9x
P/S RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | €22.99b |
| Cost of Revenue | €17.17b |
| Gross Profit | €5.81b |
| Other Expenses | €4.30b |
| Earnings | €1.51b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 05, 2026
| Earnings per share (EPS) | 2.69 |
| Gross Margin | 25.29% |
| Net Profit Margin | 6.59% |
| Debt/Equity Ratio | 51.3% |
How did FRE perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield39%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 17:51 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fresenius SE & Co. KGaA is covered by 30 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hassan Al-Wakeel | Barclays |
| Robert Bate | Barclays |
| Victoria Lambert | Berenberg |